GLADI is James Taylor constructed explicitlyto give investors

GLADI is reports steamroller james taylor constructed explicitlyto carole king it's too late investigates give investors a potential first-mover benefit as they position theirfixed income portfolios for this journey as well as for the future globallandscape.In addition to positioning for both "the journey and the destination," theindex offers a comprehensive coverage of global fixed income markets thatgoes well beyond traditional market capitalization-based approaches toindexing. It does so by making fuller use of the global fixed incometoolkit, covering opportunities in nominal and real assets as well as cashand derivatives markets. Additionally, GLADI's use of weighting based ongross domestic product incorporates a degree of counter-cyclicalrebalancing. GDP weights also help GLADI avoid allocating too heavilytoward overpriced securities and large, heavily indebted issuers.The PIMCO Global Advantage Bond Index will be administered and calculatedindependently from PIMCO by Markit LLC, an unaffiliated leading financialinformation services company and global index provider. More informationon the index, including detailed information on construction methodology,can be found at , including a link to Markit'swebsite.Certain features of the PIMCO Global Advantage Bond Index (GLADI) arepatent pending. GLOBAL ADVANTAGE and GLADI are trademarks of PacificInvestment Management Company LLC.About PIMCOPIMCO, founded in 1971, is a global asset management firm serving a fullrange of institutional and retail investors worldwide.

Our reputation asone of the world's top asset managers rests on our combination of along-term investment approach, superior client servicing and cutting edgetechnology james taylor copperline . With offices in nine countries in North America, Europe andAsia, we manage investments across a full spectrum of global financialmarkets james talor . Our success is built on our goal of consistently providingattractive returns while maintaining a strong culture of risk managementand long-term discipline carole king albums . PIMCO is owned by Allianz Global Investors, asubsidiary of the Munich-based Allianz Group, a leading global insurancecompany.About MarkitMarkit is a financial information services company with more than 1,000employees in Europe, North America and Asia-Pacific dad loves his work . Over 1,000 financialinstitutions use Markit's independent services to manage risk, improveoperational efficiency and meet regulatory requirements. Markit is aleading independent global index provider and owns, manages, administersand calculates the Markit iBoxx, Markit iTraxx and Markit CDX indices. Formore information, see for the historical information and discussions contained herein,statements contained in this news release constitute forward-lookingstatements within the meaning of the Private Securities Litigation ReformAct of 1995.

These statements may involve a number of risks, uncertaintiesand other factors that could cause actual results to differ materially,including the performance of financial markets, the investment performanceof PIMCO's sponsored investment products and separately managed accounts,general economic conditions, future acquisitions, competitive conditionsand government regulations, including changes in tax laws Readers shouldcarefully consider such factors james taylor concert . Further, such forward-looking statementsspeak only on the date at which such statements are made carole king . PIMCO undertakesno obligation to update any forward-looking statements to reflect eventsor circumstances after the date of such statements.Contact:Steven VamesPIMCO - Media Relations212-739-3598Copyright 2009, Market Wire, All rights reserved.-0- carole king sheet music . RESEARCH TRIANGLE PARK, NC, Jan 12 (MARKET WIRE) -- A recent European Commission report chastised the pharmaceutical industryfor what it claims are anti-competitive practices aimed to preventgeneric drug manufacturers from entering the market with low-pricedcopies of branded prescription medications carole king will you love me tomorrow . In the report, the Commissionclaims that big pharma's counter-generics strategies cost European Unionmember states around 3 billion euros from 2000 through 2007.The European Commission's report, which attacks the pharmaceuticalindustry for exercising its right to defend its patents and to earn areturn on the billions it invests in research and development, reflectsthe Commission's shortsighted vantage point. The Commission convenientlyignores the billions of euros of value that the pharmaceutical industryinvests in the economy, as well as the immeasurable value that theindustry's R&D innovation generates in quality-of-life improvements andoverall health improvement of the EU member nations.According to a report, "Combating Generics 2008: Counter-GenericsStrategy, Tactics and Execution" (), frompharmaceutical business intelligence leader Cutting Edge Information,when regulatory authorities like the European Commission begin to erodethe economic incentives that drive investment in innovation and new drugdiscovery and development, they put at risk the lives and well-being ofthe very populations they are charged with protecting."This European Commission report reveals that the Commission simply doesnot understand the full economic and healthcare implications of its policystance," says Adam Bianchi, chief operating officer of Cutting EdgeInformation. "Ethical drug manufacturers should have every right to filepatent infringement lawsuits to defend their intellectual property,release new and improved medications designed to replace existingtherapies, and to protect the billions they have invested to bring newmedicines to market."Cutting Edge Information's report, "Combating Generics 2008:Counter-Generics Strategy, Tactics and Execution," details the present andplanned future usage of a dozen counter-generics strategies and examinesother counter-generics activity at more than 30 different companies.

Datadetails investment levels, planning and implementation timelines and theprominence of different tools and tactics in the fight against genericcompetition . The report's findings also explore case studies and theexperiences of real-world brand teams.A complimentary brochure of "Combating Generics 2008: Counter-GenericsStrategy, Tactics and Execution" is available at INFORMATION:Adam BianchiEmail Contact919-403-6583Copyright 2009, Market Wire, All rights reserved.-0- james taylor line 'em up . On Oct fire and rain . 30, 2008, an extremely unknown rookie winger was playing in just his second career game.After receiving just 5:35 in ice time two days earlier in his first career game, it wasn't likely that Jamie McGinn would see much more time on the rink against the defending Stanley Cup Champion Detroit Red Wings.But while playing just a little over seven minutes, McGinn scored his first career goal to give the Sharks a 2-1 lead about half-way through the second period.The young forward would later add an assist, but it was his hard-working goal that made almost all Sharks fans cheer while asking the same thing: Who the heck is Jamie McGinn?In total, McGinn appeared in just 35 games last season, contributing a pedestrian six points (four goals, two assists) and a minus-six plus/minus rating.However, his work ethic and tenacity on the fore-check in limited time with the Sharks allowed for fans to have some heightened expectations for McGinn coming into this season.But early on this year, the McGinn who came out of nowhere to score that clutch goal against the Red Wings was nowhere to be found.McGinn started out tentatively the first few games which caused him to bounce back and forth from the Sharks minor league affiliate in Worcester.Time spent in the minors has meant that McGinn, 21, has played in just 13 of the Sharks' 19 games so far this season.Fortunately for McGinn, his performance of late is going to make it much harder for the Sharks to send him back to the minors any time soon.Before some of the injured Sharks started returning to action, McGinn had found some chemistry on the third line alongside Scott Nichol and Jed Ortmeyer.His play was picking up as he notched his second goal of the season on Saturday in the Sharks' 5-0 win over the Penguins.The goal was eerily similar to that of his first career tally against Detroit . McGinn simply went hard to the net, picked up a loose puck and somehow found away to sneak the puck in from beside the net.After his overall performance against Pittsburgh, head coach Todd McLellan stated that he finally saw the McGinn he was expecting coming out of training camp, "Mr.